Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer

Journal of the National Cancer Institute

Volumn 102, Issue 23, 2010, Pages 1760-1770

  Gillessen, Silke ^a   Templeton, Arnoud ^a   Marra, Giancarlo ^b   Kuo, Yong Fang ^c   Valtorta, Emanuele ^b   Shahinian, Vahakn B ^d  

^a Kantonsspital ^*  (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; SECOND CANCER; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK ASSESSMENT; TIME FACTORS;

EID: 78649893468     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq419     Document Type: Article

References (48)

1. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007;14(3): 247-254.
2. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without futamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419-424.
3. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106(8):1708-1714.
4. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164.
5. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6): 2106-2131. (Pubitemid 46726449)
6. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456.
7. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289-295.
8. Templeton A, Marra G, Valtorta E, et al. Concordant colon tumors in monozygotic twins previously treated for prostate cancer. Fam Cancer. 2009;8(2):167-171.
9. Aoki K, Nakajima A, Mukasa K, Osawa E, Mori Y, Sekihara H. Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandros-terone. J Steroid Biochem Mol Biol. 2003;85(2-5):469-472.
10. Izbicki JR, Hamilton SR, Wambach G, et al. Effects of androgen manipulations on chemically induced colonic tumours and on macroscopically normal colonic mucosa in male Sprague-Dawley rats. Br J Cancer. 1990; 61(2):235-240.
11. Pereira MA, Khoury MD. Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon. Cancer Lett. 1991;61(1):27-33.
12. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difuoromethylornithine, 16 alpha-fuoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 1991; 51(17):4528-4534.
13. Stebbings WS, Vinson GP, Farthing MJ, Balkwill F, Wood RF. Effect of steroid hormones on human colorectal adenocarcinoma xenografts, of known steroid-receptor status, in nude mice. J Cancer Res Clin Oncol. 1989; 115(5):439-444.
14. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl. 2008;29(5): 534-539.
15. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol. 2009;15(41):5141-5148.
16. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31(8):732-748.
17. Klabunde C, Potosky A, Legler J, Warren J. Development of a comorbid-ity index using physician claims data. J Clin Epidemiol. 2000;53(12): 1258-1267.
18. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98(12):839-845.
19. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107(1):28-36.
20. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98(13):920-931. (Pubitemid 44018922)
21. Putnam SD, Cerhan JR, Parker AS, et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol. 2000;10(6):361-369.
22. Keating NL, Landrum MB, Landon BE, Ayanian JZ, Borbas C, Guadagnoli E. Measuring the quality of diabetes care using administrative data: is there bias? Health Serv Res. 2003;38(6 pt 1):1529-1545.
23. Lu-Yao G, Moore DF, Oleynick J, Dipaola RS, Yao SL. Use of hormonal therapy in men with metastatic prostate cancer. J Urol. 2006;176(2): 526-531.
24. Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neo-adjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol. 1998;160(5):1685-1688.
25. McBean AM, Warren JL, Babish JD. Measuring the incidence of cancer in elderly Americans using Medicare claims data. Cancer. 1994;73(9): 2417-2425.
26. Penberthy L, McClish D, Manning C, Retchin S, Smith T. The added value of claims for cancer surveillance: results of varying case defnitions. Med Care. 2005;43(7):705-712.
27. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998;54(3):948-963.
28. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-1555.
29. Castagnetta L, Traina A, Campisi I, et al. Androgen receptor status in nontumoral and malignant human colorectal tissues. Ann N Y Acad Sci. 2002;963:322-325.
30. Meggouh F, Lointier P, Saez S. Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. Cancer Res. 1991;51(4):1227-1233.
31. Van der Flier LG, Sabates-Bellver J, Oving I, et al. The Intestinal Wnt/ TCF Signature. Gastroenterology. 2007;132(2):628-632.
32. Chen SY, Wulf G, Zhou XZ, Rubin MA, Lu KP, Balk SP. Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction. Mol Cell Biol. 2006;26(3):929-939.
33. Chesire DR, Isaacs WB. Ligand-dependent inhibition of beta-catenin/ TCF signaling by androgen receptor. Oncogene. 2002;21(55):8453-8469.
34. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene. 2003;22(36):5602-5613.
35. Shah S, Hecht A, Pestell R, Byers SW. Trans-repression of beta-catenin activity by nuclear receptors. J Biol Chem. 2003;278(48):48137-48145.
36. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991-1004.
37. Bjork J, Nilsson J, Hultcrantz R, Johansson C. Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somato-statin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29. Scand J Gastroenterol. 1993;28(10): 879-884.
38. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 1995;95(4):1897-1905.
39. Driver JA, Gaziano JM, Gelber RP, Lee IM, Buring JE, Kurth T. Development of a risk score for colorectal cancer in men. Am J Med. 2007;120(3):257-263.
40. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615-1624. (Pubitemid 40490022)
41. Sanderson M, Coker AL, Perez A, Du XL, Peltz G, Fadden MK. A multilevel analysis of socioeconomic status and prostate cancer risk. Ann Epidemiol. 2006;16(12):901-907.
42. Tavani A, Fioretti F, Franceschi S, et al. Education, socioeconomic status and risk of cancer of the colon and rectum. Int J Epidemiol. 1999; 28(3):380-385.
43. Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol. 2000;152(9):847-854.
44. Nomura AM. Body size and prostate cancer. Epidemiol Rev. 2001;23(1):126-131.
45. Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22(14):2927-2941.
46. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21(8):1447-1451.
47. Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101(8):1712-1719.
48. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen defciency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004; 89(12):5920-5926.